{"id":"ts-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Bone marrow suppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Gastrointestinal toxicity (nausea, diarrhea)"},{"rate":null,"effect":"Hand-foot syndrome"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL5910057","moleculeType":null,"molecularWeight":"407.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TS-1 is a fixed-dose combination of tegafur (a prodrug of fluorouracil), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (a orotate phosphoribosyltransferase inhibitor). Gimeracil inhibits the degradation of fluorouracil, while oteracil reduces gastrointestinal toxicity by blocking its activation in the GI tract, allowing higher systemic exposure and improved efficacy.","oneSentence":"TS-1 is an oral combination chemotherapy agent that inhibits thymidylate synthase and enhances fluorouracil activity against cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:57.548Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer"},{"name":"Colorectal cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07182565","phase":"PHASE1, PHASE2","title":"Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-11-18","conditions":"Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy","enrollment":84},{"nctId":"NCT04172402","phase":"PHASE2","title":"NGS as the First-line Treatment in Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2019-12-27","conditions":"Advanced Biliary Tract Cancer","enrollment":48},{"nctId":"NCT05065957","phase":"PHASE2, PHASE3","title":"Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"InnoPharmax Inc.","startDate":"2022-03-29","conditions":"Biliary Tract Cancer","enrollment":180},{"nctId":"NCT01286766","phase":"PHASE2","title":"Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":6},{"nctId":"NCT03814759","phase":"PHASE2","title":"Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-12-12","conditions":"Gastric Adenocarcinoma","enrollment":102},{"nctId":"NCT03252808","phase":"PHASE1","title":"Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takara Bio Inc.","startDate":"2017-09-25","conditions":"Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV","enrollment":36},{"nctId":"NCT01285557","phase":"PHASE3","title":"Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2011-04-14","conditions":"Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction","enrollment":361},{"nctId":"NCT03519074","phase":"PHASE2","title":"Cisplatin Combined with Oral TS-1 in Patients with Advanced Solid Tumors with Different Degrees of Liver Dysfunction","status":"ACTIVE_NOT_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2016-07-22","conditions":"Cancer, Liver Dysfunction","enrollment":48},{"nctId":"NCT03382600","phase":"PHASE2","title":"Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-03-26","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT06331845","phase":"PHASE2","title":"Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-05-01","conditions":"Metastatic Nasopharyngeal Carcinoma, Intermittent Systematic Chemotherapy","enrollment":39},{"nctId":"NCT05955157","phase":"PHASE2, PHASE3","title":"Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2023-01-03","conditions":"Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor","enrollment":52},{"nctId":"NCT04999332","phase":"PHASE2","title":"Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2021-12-10","conditions":"Gastric Cancer, Gastric Adenocarcinoma, Effects of Chemotherapy","enrollment":58},{"nctId":"NCT03726021","phase":"PHASE2","title":"Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Qingdao Central Hospital","startDate":"2018-01-26","conditions":"Overall Survival","enrollment":47},{"nctId":"NCT02191566","phase":"PHASE2","title":"S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy","status":"TERMINATED","sponsor":"Kangbuk Samsung Hospital","startDate":"2015-05","conditions":"Stomach Cancer","enrollment":8},{"nctId":"NCT04806646","phase":"PHASE2","title":"Tailored Sonidegib Schedule After Complete Response in BCC","status":"UNKNOWN","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2021-01-12","conditions":"Locally Advanced Basal Cell Carcinoma","enrollment":21},{"nctId":"NCT03559348","phase":"PHASE2","title":"Locally Advanced or Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-04-03","conditions":"Pancreatic Adenocarcinoma","enrollment":49},{"nctId":"NCT00429858","phase":"PHASE2","title":"Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Andrew Ko","startDate":"2007-01-22","conditions":"Pancreatic Cancer","enrollment":21},{"nctId":"NCT01761461","phase":"PHASE3","title":"Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2013-02-06","conditions":"Gastric Cancer","enrollment":547},{"nctId":"NCT00915382","phase":"PHASE3","title":"Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2009-01","conditions":"Advanced Gastric Cancer","enrollment":625},{"nctId":"NCT02301481","phase":"PHASE2","title":"A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2014-01","conditions":"Stomach Neoplasms, Neoadjuvant Therapy, Chemoradiotherapy","enrollment":71},{"nctId":"NCT02425137","phase":"PHASE2","title":"A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"TTY Biopharm","startDate":"2015-04","conditions":"Advanced Biliary Tract Cancer(BTC)","enrollment":51},{"nctId":"NCT02182778","phase":"PHASE3","title":"GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2014-07-09","conditions":"Biliary Tract Cancer","enrollment":246},{"nctId":"NCT01821248","phase":"PHASE2","title":"A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis","status":"UNKNOWN","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2013-07-23","conditions":"Biliary Tract Cancer","enrollment":25},{"nctId":"NCT01283204","phase":"PHASE2","title":"Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03-09","conditions":"Recurrent or Metastatic Gastric Cancer","enrollment":180},{"nctId":"NCT01815307","phase":"PHASE2","title":"Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2013-01","conditions":"Biliary Tract Cancer","enrollment":70},{"nctId":"NCT03517618","phase":"PHASE2","title":"TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC","status":"COMPLETED","sponsor":"TTY Biopharm","startDate":"2014-07-05","conditions":"Metastatic Colorectal Cancer","enrollment":41},{"nctId":"NCT01430052","phase":"PHASE2","title":"Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Osaka Medical Center for Cancer and Cardiovascular Diseases","startDate":"2009-04","conditions":"Pancreatic Cancer","enrollment":110},{"nctId":"NCT03316326","phase":"PHASE2","title":"S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-11-01","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":35},{"nctId":"NCT03313856","phase":"PHASE2, PHASE3","title":"Effect of Oral Administration of a Herbarium Mixture (Guazuma Ulmifolia and Tecoma Stans) on Metabolic Profile in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Centro Universitario de Ciencias de la Salud, Mexico","startDate":"2010-01-10","conditions":"Type 2 Diabetes Mellitus","enrollment":40},{"nctId":"NCT01713387","phase":"PHASE1","title":"A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2012-04","conditions":"Biliary Tract Cancer","enrollment":38},{"nctId":"NCT02527785","phase":"PHASE2","title":"Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2015-02","conditions":"Stomach Neoplasm","enrollment":44},{"nctId":"NCT01693432","phase":"PHASE2","title":"Docetaxel and S-1 for Advanced Esophageal Cancer","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2011-11","conditions":"Esophageal Neoplasms","enrollment":37},{"nctId":"NCT01693419","phase":"PHASE2","title":"S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2011-08","conditions":"Pancreas Neoplasms","enrollment":37},{"nctId":"NCT02527824","phase":"PHASE2","title":"Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2015-03","conditions":"Biliary Tract Neoplasm","enrollment":31},{"nctId":"NCT01472250","phase":"","title":"A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China","status":"COMPLETED","sponsor":"Peking University","startDate":"2011-11","conditions":"Advanced Gastric Cancer","enrollment":498},{"nctId":"NCT03137004","phase":"PHASE2","title":"Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2017-06-01","conditions":"Advanced Gastric Cancer","enrollment":47},{"nctId":"NCT01946646","phase":"PHASE1","title":"Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2013-10","conditions":"Metastatic Pancreatic Cancer","enrollment":10},{"nctId":"NCT00252161","phase":"PHASE3","title":"A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer","status":"COMPLETED","sponsor":"Haruhiko Fukuda","startDate":"2005-11","conditions":"Gastric Neoplasm","enrollment":316},{"nctId":"NCT02870153","phase":"PHASE2","title":"SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer","status":"UNKNOWN","sponsor":"The First People's Hospital of Changzhou","startDate":"2013-01","conditions":"Colorectal Neoplasm","enrollment":60},{"nctId":"NCT00660894","phase":"PHASE3","title":"Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2008-04","conditions":"Colorectal Cancer","enrollment":1535},{"nctId":"NCT01100801","phase":"PHASE2","title":"A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2010-07","conditions":"Recurrent Gastric Cancer","enrollment":90},{"nctId":"NCT01542294","phase":"PHASE1, PHASE2","title":"SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-06","conditions":"Gastric Cancer","enrollment":71},{"nctId":"NCT01980810","phase":"PHASE2","title":"First Line Chemotherapy for Advanced Cancer","status":"TERMINATED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2013-09","conditions":"Gastric Cancer","enrollment":36},{"nctId":"NCT00216034","phase":"PHASE3","title":"Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK","status":"COMPLETED","sponsor":"Hokuriku-Kinki Immunochemotherapy Study Group","startDate":"2005-03","conditions":"Gastric Cancer","enrollment":255},{"nctId":"NCT02754180","phase":"PHASE2","title":"Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2016-03","conditions":"Pancreatic Neoplasms","enrollment":110},{"nctId":"NCT01693445","phase":"PHASE1","title":"S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2012-06","conditions":"Gastrointestinal Neoplasms","enrollment":22},{"nctId":"NCT01874678","phase":"NA","title":"A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer","status":"COMPLETED","sponsor":"TTY Biopharm","startDate":"2011-03","conditions":"Non-small-cell Lung Cancer (NSCLC)","enrollment":45},{"nctId":"NCT01671449","phase":"PHASE3","title":"S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Min-Hee Ryu","startDate":"2012-12","conditions":"Gastric Cancer","enrollment":338},{"nctId":"NCT01128998","phase":"PHASE1","title":"Sorafenib Plus S-1 in Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2009-11","conditions":"Advanced Solid Tumors","enrollment":30},{"nctId":"NCT00438100","phase":"PHASE2","title":"Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Network","startDate":"2008-04","conditions":"Breast Neoplasms","enrollment":142},{"nctId":"NCT01679340","phase":"PHASE2","title":"A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery","status":"UNKNOWN","sponsor":"Peking University","startDate":"2011-04","conditions":"Gastric Cancer","enrollment":160},{"nctId":"NCT01269216","phase":"PHASE2","title":"A Study of Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin (FL) vs. TS-1/Irinotecan in Patients With Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2008-10","conditions":"Rectal Cancer","enrollment":136},{"nctId":"NCT01531452","phase":"PHASE2","title":"The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-06","conditions":"Stomach Neoplasms","enrollment":43},{"nctId":"NCT01291615","phase":"PHASE1","title":"Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2010-12","conditions":"Biliary Tract Cancer","enrollment":6},{"nctId":"NCT01284413","phase":"PHASE1, PHASE2","title":"Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2010-12","conditions":"Biliary Tract Cancer","enrollment":68},{"nctId":"NCT02146703","phase":"PHASE2","title":"Gemcitabine and S-1 for Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2005-08","conditions":"Biliary Tract Neoplasm","enrollment":38},{"nctId":"NCT01171755","phase":"PHASE2","title":"Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2008-02","conditions":"Biliary Tract Cancer","enrollment":19},{"nctId":"NCT01096199","phase":"PHASE1","title":"A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)","status":"TERMINATED","sponsor":"National University Hospital, Singapore","startDate":"","conditions":"Cancer","enrollment":35},{"nctId":"NCT01388790","phase":"PHASE2","title":"Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-06","conditions":"Gastric Cancer","enrollment":40},{"nctId":"NCT00527930","phase":"PHASE2","title":"Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2007-09","conditions":"Breast Neoplasms","enrollment":87},{"nctId":"NCT01269255","phase":"PHASE1","title":"A Trial of Induction Chemotherapy and Chemoradiotherapy With TS-1 and Cisplatin (SP) as First-line Treatment in Patients With High Risk Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-12","conditions":"Gastric Cancer","enrollment":6},{"nctId":"NCT01824004","phase":"PHASE2","title":"Postoperative Chemoradiotherapy With S-1 in Gastric Cancer","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2009-04","conditions":"Gastric Cancer","enrollment":46},{"nctId":"NCT01492543","phase":"PHASE2","title":"Study of TS-1 as 2nd Line Treatment in Patients With Advanced Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-12","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT01747707","phase":"PHASE2","title":"Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2012-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":40},{"nctId":"NCT00498225","phase":"PHASE3","title":"Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2007-07","conditions":"Pancreatic Cancer","enrollment":834},{"nctId":"NCT00284258","phase":"PHASE2, PHASE3","title":"Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2006-01","conditions":"Colorectal Cancer","enrollment":426},{"nctId":"NCT00677144","phase":"PHASE2","title":"Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2008-04","conditions":"Colorectal Neoplasm","enrollment":88},{"nctId":"NCT00525005","phase":"PHASE2","title":"Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2007-08","conditions":"Stomach Neoplasms","enrollment":44},{"nctId":"NCT01645748","phase":"PHASE2","title":"Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2008-10","conditions":"Head and Neck Cancer","enrollment":35},{"nctId":"NCT01621919","phase":"","title":"Concentration of S-1 Metabolites in Tear and Plasma of Patients Receiving TS-1","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-12","conditions":"Gastric Cancer","enrollment":200},{"nctId":"NCT01608646","phase":"PHASE2","title":"Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2012-03","conditions":"Gastrointestinal Cancer","enrollment":200},{"nctId":"NCT00687843","phase":"PHASE3","title":"Study of TS-1 or TS-1 + PSK for Gastric Cancer Patients","status":"UNKNOWN","sponsor":"Tokyo Metropolitan Oncology Group","startDate":"2008-06","conditions":"Gastric Cancer","enrollment":480},{"nctId":"NCT01533324","phase":"PHASE2","title":"S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)","status":"UNKNOWN","sponsor":"Second Military Medical University","startDate":"2011-11","conditions":"Carcinoma, Liver Diseases, Hepatocellular Carcinoma","enrollment":32},{"nctId":"NCT01131689","phase":"PHASE1","title":"Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-09","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT01426646","phase":"PHASE2","title":"S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer","status":"UNKNOWN","sponsor":"Kyungpook National University Hospital","startDate":"2011-09","conditions":"Gastric Cancer","enrollment":218},{"nctId":"NCT00659113","phase":"PHASE2","title":"S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2008-03","conditions":"Esophageal Cancer","enrollment":32},{"nctId":"NCT01429961","phase":"PHASE2","title":"Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2011-05","conditions":"Advanced Hepatocellular Carcinoma","enrollment":38},{"nctId":"NCT00805012","phase":"PHASE2","title":"Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2008-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":96},{"nctId":"NCT00152217","phase":"PHASE3","title":"Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2001-09","conditions":"Gastric Cancer","enrollment":1000},{"nctId":"NCT00150670","phase":"PHASE3","title":"Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2002-03","conditions":"Gastric Cancer","enrollment":300},{"nctId":"NCT00287768","phase":"PHASE3","title":"Phase III Study of Docetaxel + S-1 vs. S-1 for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Japan Clinical Cancer Research Organization","startDate":"2006-03","conditions":"Gastric Cancer","enrollment":628},{"nctId":"NCT00514163","phase":"PHASE2","title":"GEM vs GEM+TS-1 for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Japan Clinical Cancer Research Organization","startDate":"2007-06","conditions":"Pancreatic Cancer","enrollment":110},{"nctId":"NCT00639327","phase":"PHASE2, PHASE3","title":"Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Japan Clinical Cancer Research Organization","startDate":"2008-03","conditions":"Gastric Cancer","enrollment":300},{"nctId":"NCT01096745","phase":"PHASE2","title":"Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer","status":"TERMINATED","sponsor":"Gyeongsang National University Hospital","startDate":"2010-07","conditions":"Metastatic Biliary Tract Cancer, Locally Advanced Biliary Tract Cancer","enrollment":78},{"nctId":"NCT00960349","phase":"PHASE1","title":"Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Gastric Cancer","enrollment":14},{"nctId":"NCT00874328","phase":"PHASE1, PHASE2","title":"A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2008-10","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":74},{"nctId":"NCT00209729","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.","status":"SUSPENDED","sponsor":"Hokkaido Gastrointestinal Cancer Study Group","startDate":"2005-04","conditions":"Gastric Cancer","enrollment":50},{"nctId":"NCT00512681","phase":"PHASE2","title":"A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2007-07","conditions":"Stomach Neoplasms","enrollment":44},{"nctId":"NCT00961077","phase":"PHASE2","title":"Attenuated SOX as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Soonchunhyang University Hospital","startDate":"2009-08","conditions":"Elderly, S-1, Oxaliplatin","enrollment":36},{"nctId":"NCT00195572","phase":"PHASE3","title":"Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-05","conditions":"Gastric Cancer","enrollment":200},{"nctId":"NCT00531245","phase":"PHASE1, PHASE2","title":"A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2006-08","conditions":"Colorectal Neoplasms","enrollment":77},{"nctId":"NCT00503321","phase":"PHASE2, PHASE3","title":"Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma","status":"TERMINATED","sponsor":"Eastern Network of Cancer Immunological Therapy, Japan","startDate":"2006-10","conditions":"Gastric Cancer","enrollment":13},{"nctId":"NCT00316745","phase":"PHASE3","title":"IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer","status":"SUSPENDED","sponsor":"Hokkaido Gastrointestinal Cancer Study Group","startDate":"2006-04","conditions":"Metastatic Colorectal Cancer","enrollment":200},{"nctId":"NCT00436423","phase":"PHASE2","title":"A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2006-03","conditions":"Pancreatic Neoplasm, Neoplasm Metastasis","enrollment":38},{"nctId":"NCT00209651","phase":"PHASE2","title":"Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Hokkaido Gastrointestinal Cancer Study Group","startDate":"2004-01","conditions":"Colorectal Cancer","enrollment":40},{"nctId":"NCT00506571","phase":"PHASE2","title":"Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2007-07","conditions":"Colorecal Neoplasms, Secondary","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1357,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["S-1","Tegafur-gimeracil-oteracil potassium"],"phase":"phase_3","status":"active","brandName":"TS-1","genericName":"TS-1","companyName":"National Health Research Institutes, Taiwan","companyId":"national-health-research-institutes-taiwan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TS-1 is an oral combination chemotherapy agent that inhibits thymidylate synthase and enhances fluorouracil activity against cancer cells. Used for Gastric cancer, Colorectal cancer, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}